Tiziana Life Sciences Prepares To Advance Lead Intranasal Foralumab Program In First-Of-Its-Kind Phase 2a Clinical Trial for Non-Active SPMS Patients
SponsoredPoised For Growth? This Biotech Is Close To Beginning Key Phase 2a Study With Its Lead Candidate
SponsoredTiziana Reveals Alzheimer's Research Milestone With PNAS Journal After FDA IND Green Light
SponsoredTiziana's Intranasal Foralumab For Alzheimer's Treatment Gets FDA Nod For Phase 2 Trials Under Brigham And Women's Hospital Supervision
SponsoredTiziana Life Sciences Recent News
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
Sponsored
Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon
Sponsored
Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
Sponsored
Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment
Sponsored
Publications And Positive Data From Multiple Trials: Six Months In Review For Tiziana Life Sciences (NASDAQ: TLSA)
Sponsored
Tiziana Life Sciences (NASDAQ: TLSA) Announces Positive Data In Its Secondary-Progressive Multiple Sclerosis Trial, What Could This Mean For The Company?
Sponsored
Tiziana's Foralumab Shown To Reduce Microglial Activation In MS Patients; Phase 2a Trial To Begin In Q3 2023
Sponsored
Tiziana Life Sciences To Submit Alzheimer's IND In Q2 2023, Seeks $3 Million From An Alzheimer's Foundation To Support Phase 2a Trial
Sponsored
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
Sponsored
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise
Sponsored
Tiziana Receives Sign-Off From The FDA To Proceed With Phase 2 Clinical Trial In Patients With Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
Sponsored